Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul Peter Tak | $743,592 | $0 | $0 | $3,916,028 | $396,653 | $0 | $288,289 | $5,344,561 |
| Chief Executive Officer, President and Director | ||||||||
| Francesca Barone | 483,312 | 0 | 0 | 857,797 | 206,427 | 0 | 14,000 | 1,561,536 |
| Chief Scientific Officer | ||||||||
| Charles Schoch | 398,500 | 0 | 0 | 826,465 | 232,320 | 0 | 13,532 | 1,470,817 |
| Chief Financial Officer, Treasurer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul Peter Tak | $5,344,561 | — | — | — |
| Francesca Barone | 1,561,536 | — | — | — |
| Charles Schoch | 1,470,817 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Peter Tak | Option | 6,875 | 4.12 | — |
| Paul Peter Tak | Option | 20,000 | 1.29 | — |
| Paul Peter Tak | Option | 415,625 | 8.55 | — |
| Francesca Barone | Option | 1,667 | 4.06 | — |
| Francesca Barone | Option | 91,042 | 8.55 | — |
| Francesca Barone | Option | 2,292 | 4.12 | — |
| Francesca Barone | Option | 30,000 | 1.29 | — |
| Charles Schoch | Option | 13,166 | 1.29 | — |
| Charles Schoch | Option | 65,709 | 8.55 | — |
| Charles Schoch | Option | 50,000 | 4.75 | — |
Our executive compensation program is based on a pay-for-performance philosophy, designed to be competitive and aligned with our business and executive talent requirements.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Plc d/b/a Radford |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maha Radhakrishnan, M.DIndependent · Audit | $20,096 | $0 | $138,250 | — | $0 | $158,346 |
| Paul B. ManningIndependent · Board Chair · Compensation | 70,000 | 0 | 60,546 | — | 0 | 130,546 |
| Christopher MartellIndependent · Nominating and Corporate Governance | 54,000 | 0 | 60,546 | — | 0 | 114,546 |
| Nicoletta Loggia, Ph.D., R.PhIndependent · Audit · Nominating and Corporate Governance · Compensation | 46,473 | 0 | 60,546 | — | 0 | 107,019 |
| Edward J. Benz Jr., M.DIndependent · Nominating and Corporate Governance (Chair) | 43,000 | 0 | 60,546 | — | 0 | 103,546 |
| Renee GaetaIndependent · Audit (Chair) | 42,500 | 0 | 60,546 | — | 0 | 103,046 |
| Joseph C. Papa, R.Ph., M.B.AIndependent · Compensation | 41,264 | 0 | 60,546 | — | 0 | 101,810 |
| Gary J. Nabel, M.D., Ph.DIndependent · Nominating and Corporate Governance | 39,000 | 0 | 60,546 | — | 0 | 99,546 |
| Paul Peter Tak, M.D., Ph.D., FMedSciEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 4,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $356,333 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $356,333 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Candel Therapeutics | 2025 | Paul Peter Tak | $743,592 | $0 | $3,916,028 | $396,653 | $5,344,561 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Paul Peter Tak | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Executive Compensation”. As printed: 5,344,561. Filing ↗machine: r2 · c33 · span 520483–520492 |
| 2 | Section 01, Francesca Barone | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Executive Compensation”. As printed: 1,561,536. Filing ↗machine: r4 · c33 · span 544904–544913 |
| 3 | Section 01, Charles Schoch | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Executive Compensation”. As printed: 1,470,817. Filing ↗machine: r6 · c33 · span 569302–569311 |
| 4 | Section 08, Maha Radhakrishnan, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 158,346. Filing ↗machine: span 383254–383261 |
| 5 | Section 08, Paul B. Manning | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 130,546. Filing ↗machine: span 335369–335376 |
| 6 | Section 08, Christopher Martell | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 114,546. Filing ↗machine: span 359302–359309 |
| 7 | Section 08, Nicoletta Loggia, Ph.D., R.Ph | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 107,019. Filing ↗machine: span 353321–353328 |
| 8 | Section 08, Edward J. Benz Jr., M.D | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 103,546. Filing ↗machine: span 341356–341363 |
| 9 | Section 08, Renee Gaeta | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 103,046. Filing ↗machine: span 347329–347336 |
| 10 | Section 08, Joseph C. Papa, R.Ph., M.B.A | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 101,810. Filing ↗machine: span 377267–377274 |
| 11 | Section 08, Gary J. Nabel, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 99,546. Filing ↗machine: span 365290–365296 |
| 12 | Section 08, Paul Peter Tak, M.D., Ph.D., FMedSci | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 09b board cost (computed) | Computed | — | computed | Cash 356,333 + equity 0 + all other 0 = 356,333, summed across the director compensation table rows.machine: formula: Σ = 356,333 |
| 14 | Candel Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191506 | CEO total compensation as printed in Candel Therapeutics's own proxy. As printed: 5,344,561. Filing ↗machine: r2 · c33 · span 520483–520492 |